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Human bocavirus 1 (HBoV1), belonging to the Parvoviridae family was discovered in 2005 
in nasopharyngeal samples from children with respiratory tract infections (RTIs). Three addi-
tional bocaviruses, HBoV2-4, were discovered in 2009-2010. These viruses have mainly been 
found in faecal samples, and their role in human diseases is still uncertain. HBoV1 causes a 
wide spectrum of respiratory diseases in children including common cold, acute otitis media, 
pneumonia, bronchiolitis and asthma exacerbations. HBoV1 DNA can persist in airway 
secretions for months after an acute infection. Consequently, acute HBoV1 infection cannot 
be diagnosed with standard DNA PCR; quantitative PCR and serology are better diagnostic 
approaches. Because of their high clinical specificity, diagnostic developments such as 
HBoV1 mRNA and antigen detection have shown promising results. This review summarizes 
the knowledge on human bocaviruses, with special focus on HBoV1. 
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Ihmisen bokavirus 1 (hBoV1), joka kuuluu Parvovirusten sukuun, löydettiin vuonna 2005 
ylähengitystieinfektioita sairastaneiden lasten nenänielunäytteistä. Kirjallisuuskatsaus tiivistää 
ajankohtaista tietoa bokaviruksien genomista ja rakenteesta, epidemiologiasta, esiintyvyydestä 
muiden virusinfektioiden yhteydessä, transmissiosta, patogeneesistä, persistenssistä, diagnos-
tiikasta, kliinisestä kuvasta, vakavan hBoV1-infektion riskitekijöistä sekä hoidosta.  
 
Katsaus on jatkoa työryhmän aiemmalle kirjallisuuskatsaukselle, jossa tarkastelun kohteena 
olivat ennen 23.5.2011 ilmestyneet bokavirusta koskevat julkaisut. Tämä tutkielma perustuu 
508:aan aikavälillä 23.5.2011–30.4.2018 julkaistuun PubMed-tietokannassa oleviin englan-
ninkieliseen artikkeliin, jotka löydettiin hakusanalla ”bocavirus”. Näistä artikkeleista valikoi-
tiin merkittävät molekyylitason tutkimukset, jotka sisälsivät uutta tietoa bokaviruksen biolo-
giasta tai diagnostiikasta. Lisäksi katsaukseen sisällytettiin kliiniset tutkimukset, joissa otos-
koko oli vähintään 100 tai tutkimus sisälsi muuten arvokasta tietoa, kuten ainutlaatuisia tut-
kimusmenetelmiä tai potilasryhmiä. 
 
Katsaukseen valikoituneista tutkimuksista ilmenee, että hBoV1 on yleinen ylähengitystiein-
fektioiden aiheuttaja lapsilla. hBoV2-4 löydettiin vuosina 2009–2010. Näitä viruksia esiintyy 
pääasiassa ulostenäytteissä ja niiden merkitys sairauksien aiheuttajana on vielä epäselvä. 
hBoV1 aiheuttaa lapsilla useita eri hengitystieinfektioiden taudinkuvia, joihin kuuluvat taval-
linen flunssa, akuutti välikorvatulehdus, keuhkokuume, bronkioliitti, toistuva uloshengitys-
vaikeus ja astman pahenemisvaihe. hBoV1-DNA:ta voi esiintyä hengitysteiden eritteissä kuu-
kausia akuutin infektion jälkeen. Tämän vuoksi akuutin hBoV1-infektion diagnosoinnissa ei 
voida käyttää tavallista DNA-PCR-menetelmää. Diagnostiikassa tarkempia menetelmiä ovat 
kvantitatiivinen PCR sekä serologia. Uusilla tutkimusmenetelmillä, kuten hBoV1-mRNA -
tunnistuksella ja hbov1-antigeenintunnistuksella on saatu lupaavia tuloksia. Menetelmien klii-
ninen spesifisyys on tarkempi. 
 
Akuutin hBoV1-infektion diagnosoimiseksi suositellaan kirjallisuuskatsauksen perusteella, 
että ainakin kahden seuraavista kriteereistä tulisi täyttyä: suuri DNA-määrä tai mRNA:n 
esiintyminen nenänielueritteissä sekä positiivinen IgM, matala IgG-aviditeetti tai nelinkertai-
nen IgG-tason kasvu pariseeruminäytteissä. 
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Summary 
Human bocavirus 1 (HBoV1), belonging to the Parvoviridae family was discovered in 2005 
in nasopharyngeal samples from children with respiratory tract infections (RTIs). Three 
additional bocaviruses, HBoV2-4, were discovered in 2009-2010. These viruses have mainly 
been found in faecal samples, and their role in human diseases is still uncertain. HBoV1 
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causes a wide spectrum of respiratory diseases in children including common cold, acute otitis 
media, pneumonia, bronchiolitis and asthma exacerbations. HBoV1 DNA can persist in 
airway secretions for months after an acute infection. Consequently, acute HBoV1 infection 
cannot be diagnosed with standard DNA PCR; quantitative PCR and serology are better 
diagnostic approaches. Because of their high clinical specificity, diagnostic developments 
such as HBoV1 mRNA and antigen detection have shown promising results. This review 
summarizes the knowledge on human bocaviruses, with special focus on HBoV1. 
Key messages 
 Human bocaviruses (HBoVs) are common in humans 
 Four types of designated HBoV have been described HBoV1-4  
 HBoV1 is associated with respiratory tract infections in children 
 HBoV2-4 are mainly detected in fecal samples and their pathogenic potential is 
uncertain 
 HBoV1 infection should not be diagnosed on the basis of HBoV1 DNA detection 
alone 
 Quantitative HBoV1 DNA analysis, serology or HBoV1 mRNA detection are 
recommended diagnostic approaches 
 
Introduction 
Human bocavirus 1 (HBoV1) was discovered in 2005, in nasopharyngeal aspirates 
from children with respiratory tract infections, and belongs to the Parvoviridae family. The 
closest relatives to HBoV1 are found in animals, whereas the well-known human parvovirus 
B19 is more distantly related.
1
 Accumulating evidence, since 2005, has been obtained in 
support of HBoV1 being a genuine human pathogen causing mild to severe respiratory tract 
infections in children.
2-13
 Because of the absence of animal models for HBoV1 infection, the 
evidence is mainly epidemiological and clinical, including both case-control and longitudinal 
studies using stringent diagnostic criteria based on serology, quantitative PCR, HBoV1 
monoinfection, or HBoV1 mRNA detection.
14
 HBoV1 can be detected in airway samples 
from up to a quarter of children with upper or lower respiratory tract infections (appendix).  
 Since 2009, three additional bocaviruses designated HBoV2–4 have been discovered.15-17 
These viruses have mainly been detected in faecal samples with detection ranging from 1% to 
more than 40% in children both with and without gastrointestinal illnesses (appendix). HBoV 
DNA has also been detected in serum, cerebrospinal fluid, urine, tonsillar tissue, tumour 
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tissue and even in sewage and river water.
2,18-24
 Clinical implications of these non-respiratory 
findings are uncertain. 
From a clinical perspective, HBoV1 seems to be the most important of the human bocaviruses 
and should be part of a standard test repertoire for respiratory tract infections in children 
admitted to hospital. However, detection of HBoV1 DNA in nasopharyngeal aspirates from 
healthy children is also common, which leads to a low clinical specificity for the widely used 
HBoV1 DNA PCR method.
2,7,13,25
 Therefore, accurate diagnosis of HBoV1 infections should 
not be based on qualitative PCR alone. During the past 10 years, improved diagnostic 
approaches based on serology, quantitative DNA analysis, mRNA detection, and antigen 
detection have been developed.
2,8,11,12,26
 Despite the high prevalence of paediatric HBoV1 
infections, the virus is still not recognised by many clinicians. In this Review, we give an 
overview of the knowledge regardingt human bocaviruses with an emphasis on clinical 
features and diagnostic implications. The epidemiology, basic virology, and pathogenesis of 
bocaviruses are briefly discussed. 
 
Search strategy and selection criteria 
We searched the PubMed database for articles published in English between May 23, 2011, 
and April 30, 2018, with “bocavirus” as a search term (508 hits). Of those articles, we only 
included major molecular studies (new data on the bocavirus biology or diagnostics) and 
clinical studies (sample size over 100 cases unless otherwise valuable ie, unique diagnostics 
or patient groups). For an overview of literature published before May 23, 2011, we refer 
mainly to previous reviews on human bocaviruses.
14,27
 
 
Virus genome and structure 
Parvoviruses are small (approximately 25 nm) non-enveloped viruses, with icosahedral T=1 
capsid symmetry and a linear single-stranded DNA genome of 4-6 kb in length, with 
palindromic hairpin structures at both ends. One full-length HBoV1 genome (including 
hairpin ends) has been sequenced and it is 5543 nucleotides (nt) long with non-identical 
terminal hairpins of 140 nt and 122 nt (GenBank number JQ923422).
28
 Most of the 
encapsidated HBoV1 DNA strands have a negative polarity.
29
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The HBoV1 genome contains two main reading frames, the left (3’) half of the negative-
strand genome encoding the non-structural NS1-4 proteins, and the right (5’) half encoding 
the structural capsid proteins VP1-3, where VP3 is the major capsid protein (figure 1).
14,30-33
 
Unlike other parvoviruses, bocaviruses also have a smaller third middle reading frame 
encoding a unique nuclear protein, NP1, important in viral DNA replication and mRNA 
processing.
34,35
 HBoV1 has been shown to express a 140 nt non-coding RNA (Boca SR) at the 
right-hand side of the negative-sense genome that is required for NS protein expression.
36
 
Intraspecies recombination has been shown for all four human bocaviruses,
17
 and a 
recombination event between HBoV1 and a common ancestor of HBoV2 and HBoV4 might 
have led to the formation of HBoV3.
37
 
The HBoV1 capsid follows the typical parvovirus structure comprising 60 copies of the major 
capsid protein motif. The capsid structure has been determined to 2.9Å resolution by cryo-
electron microscopy and three dimensional image reconstruction.
38
 The inner core of the 
capsid is formed by an -helix and an eight-stranded -barrel structure, typical of 
parvoviruses.
39
 Long amino acid loops between the -strands shape the surface of the capsid. 
Some features of this topology are shared with many other parvoviruses, including an open 
channel at the 5-fold axes with a surrounding depression, another depression at the 2-fold axes 
and protrusions at the 3-fold axes. The 5-fold channel is used for externalisation of VP1u, 
packaging, and uncoating of viral DNA. HBoV1-specific variable-loop regions, which are 
important for infectivity and antigenicity have also been identified on the capsid.
38
 The viral 
capsid surface is involved in many processes, including host tropism, cell recognition, 
intracellular trafficking, genome packaging and the immune response.
38,39
 
 
Figure 1: Human bocavirus 1 genome structure 
The 5543 nucleotide human bocavirus 1 linear negative-sense single-stranded DNA genome with hairpin termini is depicted as a black line, 
with the P5 promoter as a black arrow. Below the genome, open reading frames are depicted in blue and red boxes for the non-structural 
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(NS1-4 and NP1) genes and in green for the overlapping structural (VP1-3) genes, expressed in a ratio of 1:1:10. The non-coding RNA 
(Boca SR) is depicted in red. Spliced introns are indicated as thin lines. 
Epidemiology 
In several worldwide clinical studies, HBoV1 has been one of the most commonly detected 
respiratory viruses in young children with respiratory tract infections (figure 2). By using 
qualitative PCR analysis of respiratory tract secretions, HBoV1 DNA has been detected in 
0.7-25% of children with upper respiratory tract infections and 0.8-23% with lower lower 
respiratory tract infections (appendix). However, because of the persistence of the virus, some 
studies have also detected HBoV1 DNA at a similar prevalence in healthy controls.
7,13,25,40,41
 
HBoV1 DNA has mainly been detected in children younger than 5 years old, both with and 
without respiratory tract infections.
13,25,42,43
 HBoV1 appears throughout the year, and no clear 
seasonality has been observed in epidemiological studies that controlled for sampling 
frequency.
7,13
 In adults with respiratory illness, HBoV1 has been detected in less than 10% of 
cases, and in most studies, less than 1% of cases (appendix). 
HBoV2-4 DNA has been detected mainly in faecal samples (Appendix). However, the 
prevalence of human bocaviruses in patients without diarrhoea is similar to that in patients 
with gastrointestinal diseases.
44
 Importantly, HBoV2 DNA has been shown to be present in 
faecal samples for months, possibly explaining the similar prevalence.
8
 HBoV1 has also been 
detected in faeces, presumably representing the intestinal passage of the viruses secreted from 
the respiratory tract in children either with or without accompanying respiratory symptoms.
44
  
 
The prevalence of acute HBoV1 infections could only be determined after the development of 
serodiagnosis. In one study, maternal antibodies were shown to be present in 90% of children 
younger than 3 months old, after which seropositivity decreased, reaching low antibody 
detection when the child was between 6 and 12 months.
45
 After infancy, HBoV 
seroprevalence increases until age 6 years, by which time 90-100 % of children have 
circulating antibodies against at least one of the four human bocaviruses.
8,46
 HBoV1 IgG 
antibody concentrations remain high during adulthood, probably because of the immunity 
boost caused by circulating HBoV1 or by an infection of related HBoV2, HBoV3, or 
both.
8,9,46,47
 Antibody cross- reactivity can occur between the different bocaviruses, but 
this problem can be overcome by blocking the antibodies recognising common epitopes by a 
competition enzyme immune-assay.
8,46
 At age 6 years, the seroprevalence of HBoV1 is 
already around 80%, for HBoV2 it is 50%, for HBoV3 10%, and for HBoV4 it is close to 
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zero, when cross reactivity is controlled for.
8,46
 However, immunological so-called original 
antigenic sin results in further complication by giving an underestimate of the seroprevalence. 
If a child has encountered an HBoV2 infection before the HBoV1 infection, a specific 
antibody response will not always be induced to HBoV1, but instead the child will show a 
boosted HBoV2 response.
8,48
 An estimation can be made that no more than 20-25% of 
patients positive for HBoV1 DNA have an acute infection on the basis of serodiagnosis.
2,8
 
 
 
Figure 2: Geographical distribution of HBoV1-4 detected in patients with respiratory, gastrointestinal, and other diseases 
HBoV=human bocavirus. Other diseases include encephalitis, hepatitis, tonsillitis, and malignant tumours. Values indicate percentages of 
each virus detected in each disease group for each region. 
Co-detections 
Multiple viral detections are common in the respiratory tract of young children, and HBoV1 is 
frequently detected together with other respiratory viruses (appendix). In as many as three 
quarters of HBoV1 DNA-positive respiratory samples, at least one other respiratory pathogen 
can be detected.
13,40,49-51
 Prolonged shedding, lasting for months after the primary infection, 
has been demonstrated in a number of studies.
7,9,40,41,52,53
 Additionally, according to one 
longitudinal study of saliva in infants, a third of the first encounters with HBoV1 might occur 
without associated new-onset cough or rhinorrhoea. However, whether those encounters were 
acute primary infections, saliva contaminations of other day-care infants, or whether these 
children had maternal antibodies protecting them from disease was not verified.
7
 Given the 
prolonged shedding of HBoV1 and the fact that children younger than age 2 years can have 
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from  six to ten respiratory infections per year,
54
 DNA from HBoV1 might frequently be co-
detected with other infections and also be observed in asymptomatic children. 
However, even in respiratory samples containing actively transcribing HBoV1, other viruses 
have been detected in almost 60% of the cases.
12
 This detection raises the question of whether 
HBoV1 also has a more active or synergetic role in multiple respiratory infections. A few on 
HBoV1 have been published;
 2,13,43,49,55,56 
however, investigating the interactions between 
respiratory viruses is demanding because large patient and control groups are needed to get 
enough samples containing each virus combination in question. Good evidence supporting the 
hypothesis that other viruses would modify HBoV1 symptomatology by acting either 
synergistically or antagonistically has not been provided. However, one study showed that 
HBoV1 suppressed rhinovirus-associated immune responses.
55
 In the study, HBoV1 was 
associated with a reduction of rhinovirus’ potential to cause new wheezing episodes for up to 
2 years after the acute infection. This finding could be valuable and warrants further study. 
Detection of other gastrointestinal viruses in HBoV2-positive and HBoV3-positive faecal 
samples from children with gastroenteritis have also been shown (appendix). In 44-100% of 
the samples, at least one other gastrointestinal virus has been detected. However, the 
prolonged shedding of HBoV2 in faecal samples could be interfering with the interpretation 
of results.
8
 The occurrence of HBoV4 in studies done so far has been too low for any 
conclusions to be drawn. 
 
Transmission 
HBoV1 DNA has primarily been detected in samples from the respiratory tract and is most 
likely transmitted through the respiratory route (appendix). Conversely, HBoV2-4 has been 
detected in faecal samples and spread most likely faecal-oral route (appendix). Vertical 
transmission of human bocaviruses from mother to fetus has not been shown. HBoV DNA has 
been detected in plasma from healthy children and adults (including blood donors);
 57-59
 
however, whether this detection represents transmissible viruses or circulating non-infectious 
HBoV DNA remains to be determined. In another study, HBoV DNA was not detected in any 
of 48 batches of coagulation factor products.
60
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Pathogenesis 
Because of the difficulty of culturing replicative viruses with cell lines, and the absence of 
experimental animal models to mimic infection, the pathogenesis of human bocaviruses has 
been poorly studied .
27
 However, studies have identified the mechanisms of HBoV1 infection 
in human cells. HBoV1 has been shown to disrupt epithelial barrier function
 28,61
 and induce a 
DNA damage response in in-vitro polarised airway epithelia cultures.
62
 HBoV1 infection 
induces NLRP3 inflammasome activation and caspase 1-induced cell death mediated by 
pyroptosis. Additionally, epithelial cells produce high amounts of interleukin (IL)-1α and IL-
18 throughout the course of infection, which also leads to the death of bystander cells. Anti-
apoptotic genes BIRC6 and IFI6 are upregulated in epithelial cells upon HBoV1 infection. 
The skewing of cells into pyroptosis as opposed to apoptosis has been postulated as a 
mechanism for HBoV1 to establish a persistent infection.
63
 
Patients with infections caused by HBoV1 show elevated concentrations of interferon (IFN)-
γ, IL-2 and IL-4.64 In-vitro stimulation of CD4 T cells with HBoV1 virus-like particles causes 
increased secretion of IL-10, IFN-γ and IL-13. On the other hand, the induction of T-helper-2 
cytokines and pro-inflammatory molecules upon HBoV1 infection has been suggested as a 
factor contributing to asthma exacerbations.
65,66
 On the other hand, HBoV1 has also been 
associated with markedly reduced rhinovirus-induced T-helper-1 and T-helper-2 
proinflammatory responses.
55
 
Persistence 
HBoV1 DNA has been detected in the nasopharynx of children up to 12 months after the 
primary infection.
7
However, whether HBoV1 can establish latency by integration into the 
host cell genome or as an episome remains unknown.
67
 As mentioned previously, the 
prolonged presence of the virus in the airways is a possible explanation for the high detection 
among healthy children observed in most clinical studies. Prolonged and intermittent HBoV1 
excretion after primary infection has been documented in both immunocompetent and 
immunocompromised children.
7,52,53,68-70
 The mechanisms of persistency, reactivation and 
reinfection of HBoV1 are poorly understood. However, a few studies have shown that HBoV1 
DNA is common in tonsillar tissue from children with hypertrophic tonsils.
23,71,72
 These 
9 
 
 
findings indicate that tonsils, and adenoids might be the source of prolonged HBoV1 shedding 
and that they are interesting targets for future studies on HBoV1 persistence. 
 
Diagnosis 
The diagnosis of acute viral respiratory tract infections usually relies on qualitative PCR-
based assays detecting virus genomes in respiratory samples. However, for the diagnosis of 
HBoV1 infections,  use of such assays is not feasible as the prolonged persistence of HBoV1 
DNA in the airways complicates the interpretation of a positive test result.
7,9,40,41,52,53
 The 
detection of HBoV1-specific IgM and of an increase or seroconversion of IgG provides a 
higher specificity than qualitative PCR-based assays.
2
 Serological tests could have low 
sensitivity during acute infections because of late seroconversion (figure 3). However, a 
positive IgM together with low IgG avidity, or a 4-fold increase of IgG titre, in paired serum 
samples, are criteria ensuring a specific diagnosis of acute HBoV1 infection.
2,73
 However, two 
caveats interfere with serodiagnosis of HBoV1-4: cross-reactivity and original antigenic sin, 
both of which need to be taken into consideration when doing HBoV1 serodiagnosis .
8,48
 
Some studies have focused on the clinical value of a high HBoV1 DNA load (a load more 
than 10
4
 or 10
6
 copies per mL) in respiratory secretion, but their results have been 
conflicting.
2,4,7,13,40,49
 The conflict results can be explained by confounding effects of varying 
frequencies of co-detections in the patient and control groups, type of diagnostic reference 
method, sample type, or varying quantitative PCR test performances. Studies that use HBoV1 
serology or mRNA detection as reference standard have reached more consistent results and 
can provide a basis for defining a clinical cut-off quantity.
2,11,12,74
 Concentrations from 10
4
 to 
10
8
 HBoV1 DNA copies per mL of nasopharyngeal secretions have been suggested to 
indicate acute HBoV1 infection.
2,7,11,12,74
 With HBoV1 mRNA as the reference for the 
performance of quantitative PCR (>10
6
 copies per mL), sensitivity of 100%, specificity of 93 
– 99% and positive predictive values (PPV) of 56-87% have been reported.12,74 With 
serodiagnosis as standard, the performances of quantitative PCR sensitivity was 81%, 
specificity was 92%, and PPV was 87%.
74
 Moreover, in another study, eight (38%) of 21 
symptomatic children with HBoV1 DNA loads less than 10
4
 copies per mL had a 
serologically confirmed acute infection, compared with 27 (96%) of 28 children with DNA 
loads more than 10
4
 copies per mL.
2
 Therefore, the clinical sensitivity of measuring high 
HBoV1 DNA loads seems to be moderate.  
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Presence of HBoV1 DNA in plasma or serum (DNAemia) seems to be specific for acute 
HBoV1 infections. DNAemia is rarely detected in controls,
2,8,13
 although it has been detected 
in healthy blood donors.
57,58
 The clinical sensitivity of this test is uncertain and in one study 
was found to be lower than the sensitivity for HBoV1 mRNA detection.
12
 The duration of 
DNAemia during the acute infection is short.
2,9
 
Other promising diagnostic approaches are the detection of HBoV1 mRNA by RT-PCR or 
HBoV1 antigen by immunodetection.
12,26
 Studies on the HBoV1 mRNA test have shown high 
specificity for children with upper or lower respiratory tract infections.
10-12,74
 The clinical 
sensitivity of the test depends on the duration of HBoV1 mRNA expression in the 
nasopharynx, and follow-up studies to address this question are needed. Antigen tests 
generally have lower sensitivities than tests based on nucleic acid detection. However, antigen 
tests are simple and robust tests that are well suited for outpatient use. Considering the very 
low specificity of HBoV1 DNA PCRs, antigen tests might provide an overall improvement, 
even with a lower sensitivity. An automated HBoV1 antigen test was released in 2014, and 
further investigation regarding the test’s sensitivity and specificity are underway.26  
We recommend that at least two of the following five factors should be present for the 
diagnosis of an acute primary HBoV1 infection: high DNA load by quantitative PCR (>10
6
 
HBoV1 DNA copies per mL of nasopharyngeal secretions), HBoV1 mRNA in 
nasopharyngeal secretions, positive IgM, low IgG avidity, or a 4-fold increase or more of IgG 
levels in paired serum samples. Since the role of HBoV2-4 in gastrointestinal diseases has not 
yet been clarified, diagnostic recommendations cannot be given for these viruses. 
 
Clinical features 
The clinical manifestations of a respiratory tract infection caused by HBoV1 are very similar 
to those of respiratory tract infections caused by other respiratory viruses, the most common 
being cough, fever, common cold, dyspnoea, diarrhoea and vomiting.
7,41
 In hospital-based 
studies, the most frequent diagnoses have been rhinitis, acute otitis media, pneumonia, 
bronchiolitis and asthma exacerbations.
13,49,51,75
 In case-control studies, statistically significant 
associations have been found between HBoV1 (DNAemia, monoinfection, or high HBoV1 
DNA load in nasopharyngeal aspirate) and lower respiratory tract infections.
13,49,75
 
Population-based studies with control groups have shown associations between HBoV1 (high 
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HBoV1 load or serodiagnosis) and symptoms of upper respiratory tract infections such as 
cough and rhinorrhoea, and the diagnosis of acute otitis media.
7-9
 
In studies comparing HBoV1 infections with respiratory syncytial virus infections, 
bronchiolitis seems to be more common among children infected with respiratory syncytial 
virus, and pneumonia among children infected with HBoV1. 
2,43,51
 These differences might 
occur because of differences in patient age. HBoV1-induced bronchiolitis ranks third after 
respiratory syncytial virus and rhinovirus-induced bronchiolitis, and disease severity appears 
similar when age differences are adjusted for.
2
 17 cases of severe, life-threatening and even 
fatal respiratory HBoV1 infections have been reported.
76-85
 Most of these studies have been 
done in children younger than 2 years old with lower respiratory tract infections and 
respiratory failure. Ten of the children were born prematurely and seven had no known 
previous illnesses or risk factors. HBoV1 was the sole virus detected in all cases, and in four 
cases the diagnosis was confirmed by serology.
78,80,83,84
 The most common clinical 
manifestation was an obstructive lower respiratory tract infection (figure 4). Two of the 
children died from respiratory failure. Furthermore, HBoV1 can exacerbate chronic 
pulmonary diseases like asthma, chronic obstructive pulmonary disease, and cystic 
fibrosis.
86,87
 
C-reactive protein concentrations and white blood cell counts are usually within normal 
concentrations or only slightly elevated during acute HBoV1 infections.
2,43,49
 Chest 
radiography frequently shows peribronchial or interstitial infiltrates, hyperinflation or 
atelectasis.
43,51,75
 In one study, interstitial infiltrates were observed in 75% of children 
hospitalised with lower respiratory tract infections that were associated with serologically 
confirmed HBoV1 infections.
88
 
In controlled studies on adults and patients older than 65 years, HBoV1 DNA has rarely been 
detected in respiratory samples from patients with or without a respiratory tract infection 
(appendix). Additionally, sample sizes have been too small for conclusions to be drawn on the 
clinical significance of the results. 
HBoV2-4 DNA has been detected almost exclusively in faecal samples, but their causal role 
in gastrointestinal disease is uncertain. For HBoV2 and 3, equal prevalence has been found in 
asymptomatic children and in children with gastroenteritis (appendix). Additionally, studies 
investigating viral DNA load and serology have not shown associations with gastrointestinal 
disease.
44,89
 Diagnostic challenges similar to those described for respiratory tract infections 
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are present because of persisting viruses. Further studies based on serology, viral DNA load, 
and parameters for viral gene expression are needed for elucidating the full role of human 
bocaviruses in gastroenteritis. For HBoV4, detection has been too low for any conclusions to 
be drawn on disease associations. 
A few case reports have been published describing encephalitis, hepatitis, and myocarditis in 
patients infected with HBoV1 – 3.18-22,90 Although no studies have proved a causal relation, 
the cases of encephalitis are especially intriguing because HBoV1 – 3 were the only infectious 
agents detected in cerebral spinal fluid.
18,20,21
 In one study, whole parvovirus particles were 
detected in cerebral spinal fluid by electron microscopy.
18
 HBoV1 DNA has been detected in 
tissue from hypertrophic tonsils or adenoids in children.
23,71,72
 The pathogenic role of the 
viruses in these tissues remains uncertain. 
Due to the high prevalence of HBoV antibodies in adulthood, primary infections are probably 
extremely rare in pregnancy. HBoV infection has not been detected in stillborn children or 
hydrops fetalis.
91,92
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Figure 3: Temporal pattern of clinically relevant variables through the course of an acute primary HBoV1 infection 
HBoV1=human bocavirus 1. NPA= nasopharyngeal aspirate. Development of HBoV1 DNA load in NPA is shown by the red curve. All 
other parameters are represented qualitatively by blue bars. Dotted ends of the blue bars indicate variation or uncertainty. 
Risk factors 
Risk factors for severe HBoV1-associated illness are similar to those for respiratory viral 
infections: underlying chronic medical conditions such as cardiac or pulmonary disease, 
prematurity with chronic lung disease, cancer or immunosuppression. Many cases of severe 
illness associated with HBoV1 have been published in these patient groups.68,69,93,94 As 
HBoV1 infections seem to produce a long-lasting, high-avidity IgG antibody response,
2,73
 a 
suppressed B-cell immunity would expectedly increase the risk of HBoV1 infection. In 
immunocompromised patients, the detection of HBoV1 DNA in respiratory samples has been 
reported to be associated with fever, lower respiratory symptoms, seizures, encephalitis, 
hepatitis, and gastrointestinal symptoms.
69,70,95,96
 However, HBoV1 DNA has also been 
detected in the blood of asymptomatic immunocompromised children,
 97
 and one patient 
showed a prolonged DNAemia for more than 4 weeks. Further studies are needed to clarify 
the role of both acute and persistent HBoV infections in immunocompromised patients. 
Young age can be considered a risk factor for infection with HBoV1, as these infections occur 
most commonly in children younger than 2 years old.
7,13,27
 However, maternal antibodies can 
protect children younger than 6 months old.
45
 Other risk factors for HBoV1-induced 
respiratory illness among children younger than 1 year old are maternal smoking, winter birth 
time, and a family history of asthma.
41
 Atopy (allergen-specific sensitisation) is not associated 
with HBoV1 infection among wheezing children.
98
 Human bocaviruses have also been 
detected in sewage and river water, thus raising the question of whether proximity to sewage 
could be a further risk factor.
24
 The clinical implications of these findings have not yet been 
elucidated. 
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Figure 4: Chest radiograph of 10-month-old girl with bocavirus-induced pneumonia 
A 10-month-old girl who had bocavirus-induced pneumonia was an A-gemini born at gestational week 28 and 6 days. Her weight at birth 
was 1115 g and neonatal period was non-complicated. She received propranolol hydrochloride medication to treat small skin hemangiomas. 
The illness started with symptoms of the common cold (stuffy nose, cough) a day before admission to the pediatric emergency room of 
Turku University Hospital, Turku, Finland. At examination her general condition was good and oxygen saturatio 97%, but respiratory rate 
was at the upper limit (48 breaths per min).Human bocavirus 1 (HBoV1) was detected by using a rapid antigen detection test (Maripoc, 
Turku, Finland). The mild respiratory distress was relieved by salbutamol inhalation and she was discharged. However, she came back to the 
emergency room later that day. Lung mucus viscosity was increased, she was tired, and the respiratory distress was advanced (respiratory 
rate 60 breaths per min, obstructive lung auscultation).Her C-reactive protein 1 mg/L and blood leukocyte count 10.4 10e9/l. Salbutamol 
helped only partially and she was admitted to the regular ward. The next day her general condition collapsed, she was hypotonic, and 
reporting breathing difficulties. She was admitted to the pediatric intensive care unit where her venous blood pH was 7.22,partial pressure of 
carbon dioxide was 7.3, base excess -5, bicarbonate was 19.3. A chest radiograph was suggestive of viral pneumonia. The complete 
respiratory virus panel was tested from nasopharyngeal sample with PCR in the Department of Virology, University of Turku, Turku, 
Finland. HBoV1 (high concentration) was the only positive finding. She was stabilized by continuous salbutamol inhalation, intravenous 
corticosteroid, and discontinuation of propranolol hydrochloride. HBoV1 was also detected in her plasma by PCR. After 2 days she was 
relocated back to regular ward where she received regular salbutamol inhalations and amoxycillin for acute otitis media infection. Finally, 2 
days later, she was discharged from the hospital. In the follow-up call 3 days later, the patient appeared to have improved. Propranolol 
hydrochloride was continued and she did not relapse. 
Treatment 
HBoV infections do not yet have an approved specific treatment, and no comparative studies 
on antiviral drugs have been done. Prednisolone was not found effective in a pos-hoc analysis 
of a randomised controlled trial on wheezing children with serologically confirmed HBoV1 
infection.
99
 Therefore, the treatment of choice is supportive care and the most important types 
are bronchodilation and respiratory support for children with severe bronchiolitis, wheezing, 
or pneumonia. Although HBoV1 has been associated with acute respiratory infections, the 
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disease is often self-limiting and uncomplicated. No specific preventive measures are 
available. 
 
Further research 
Good progression has been made regarding the epidemiology and diagnostics of HBoV1 
infections; however, several areas remain for which relatively little is known. No exact data 
regarding transmission of the virus or incubation time exists. Reports concerning HBoV1 
pathogenesis are scare and partly contradictory, and cell tropism, cytokine responses, 
immunogenicity, tissue persistence, and role in asthma development remain unknown. To 
learn whether HBoV1 can truly modify responses of other virus infections, and via which 
mechanisms, is of crucial importance. Prolonged respiratory shedding of HBoV1 is clearly 
common, but the mechanisms and form of its persistence are not known. Although HBoV1 
can cause severe and even fatal lower respiratory tract infections, specific treatment or 
prophylaxis remains unavailable.  
 
Conclusions 
Increasingly evidence shows that HBoV1 is an important respiratory pathogen. Overall, a 
substantial amount of data are now available regarding HBoV1, whereas relatively little is 
known about other human bocaviruses. Although most studies have been based on PCR 
detection of HBoV1 in respiratory tract secretions, only few have confirmed the HBoV1 
diagnosis with more specific procedures. Application of more stringent diagnostic methods 
and criteria will be crucial for the future. Our recommendation is that at least two of the 
following five factors should be present in diagnosing acute primary HBoV1 infection: high 
DNA load in nasopharyngeal secretions, mRNA present in nasopharyngeal secretions, 
positive IgM, low IgG avidity, or 4-fold increase in IgG titre in paired serum samples. 
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Appendix 
Major studies on human bocavirus respiratory tract infections in children using qPCR, published May 23. 2011 to April 30. 2018 (see Jartti et al 2011 for an overview of 
earlier publications). References are listed below in supplementary. 
  1st author  Study site Study year    n Age 
(years) 
Symptoms HBoV DNA +, 
n (%) 
Copy number 
(copies/ml) 
 
HBoV1 
Serodiagnosis 
n (%)  
Viruses 
tested 
Total viral co-
detections % 
HBoV co-
detections with 
other viruses, n 
(%) 
Total viral 
detections % 
Nunes1 South-
Africa 
2000 – 
2002 
943 || <2 LRTI 125 (13·3) NA ND 16 28·7 * 93 (74·4) 54 
Nascimento-
Carvalho2 
Brazil 2003 – 
2005  
268 || <5 CAP 62 (23) 26 > 10^4,  
36 (low load) 
21 (8) †† 17 † NA NA NA 
Nokso-
Koivisto3 
USA 2003 – 
2007  
707 || 6 – 35 
months 
URTI and 
AOM 
HBoV1: 172 
(24) 
2·7 x10^10 ND 15 44·1 * 128 (74·4) * 77 
Pettigrew4 USA 2003 – 
2007 
640 || 6 
months 
– 3 
years 
AOM 157 (25) 3·23x10^3 – 
1·73x10^12 
ND 3 21·5 * NA 51·0 
Pogka5 
 
Greece 2005 – 
2008 
1272 ≤ 18 ILI 81 (6·4) * LOD: 15 ND 16 21·3 * 48 (59·3) * 64 
Honkinen6 Finland 2006 – 
2007 
76 6 
months 
– 15 
years 
CAP 14 (18) NA ND 18 41·8 * 11 (79) 72 
Deng7 China 2006 – 
2009 
186 23·4 
months 
(mean) 
LRTI 31 (16·7) * < 500 – 1x10^9 ND 11 NA 19 (61·3) 67·7 * 
Rodrigues da 
Silva8 
Brazil 2007 260 <3 LRTI 27 (10·4) NA ND 13 65 25 (92·6) 85 
  
Ursic9 Slovenia 2007 – 
2009 
891 || ≤ 17 ARTI HBoV1: 164 
(18·4) 
2·0x10^3 – 
9·1x10^10 
ND 11 24·7 98 (59·8) 75 
Chonmaitree10 USA 2008 - 2013 394 || ≤ 1 URTI 3 (0·8) * 2·85x10^5 
(median viral 
load among all 
viruses) 
ND 13 39·8 * NA 76 
Akinloye11 
 
Nigeria 2009 246 children ARTI 6 (2·4) * NA ND 12 16 5 (83·3) 77 
Hao12 China 2009 – 
2011  
846 ≤ 16 RTI HBoV1: 112 
(13·2) 
NA ND 8 72·2 ¶ 67 (59·8) NA 
Liu13 
 
China 2009 – 
2012 
4242 ≤ 14 ARTI 125 (2·9) * NA ND 17 † 21·3 † 57 (45·6) † 55·7 † 
Chen14 
 
China 2009 – 
2012 
7626 < 14 LRTI 502 (6·6) NA ND 10 † 11·1 *, † 146 (29·1) † 45·8 † 
Zhao15 
 
China 2009 – 
2012 
554 < 5 LRTI HBoV1: 39 
(7·0) 
1·4x10^3 - 
5·0x10^9 
ND 19 13·7 * 19 (48·7) 61·2 * 
Feng16 China 2009 - 2013 5298 <6 
months 
ALRI 126 (2·4) * NA ‡‡ 7 23·1 * 413 (75) ‡ 48·5 * 
3333 6 – 11 
months 
ALRI 110 (3·3) * NA ‡‡ 7 25·3 *  50·4 * 
3337 12 – 23 
months 
ALRI 137 (4·1) * NA ‡‡ 7 23·5 *  48·8 * 
5159 
 
2 – 4  ALRI 116 (2·2) * NA ‡‡ 7 17·7 *  42·8 * 
2618 5 – 9  ALRI 29 (1·1) * NA ‡‡ 7 14·7 *  30·4 * 
  
 
892 
 
10 – 14  ALRI 7 (0·8) * NA ‡‡ 7 17·2 *  23·4 * 
Zhou17 
 
China 2009 – 
2013  
1229 1 – 203 
months 
RTI HBoV1: 127 
(10·3) * 
<500 – 
3·8x10^11 
ND 15 40·8 * 61 (48) 53·1 
Cui18 
 
China 2010 - 2011 1074 < 16 ARTI 78 (7·3) * NA ND 21 46·9 * 54 (69·2) * 82·3 
Kaida19 
 
Japan 2010 – 
2011 
1044 <6 ARTI HBoV1: 176 
(16·9) * 
NA ND 19 43·5 152 (86·4) 85·3 
Xu20 
 
China 2010 – 
2011 
1686 ≤ 15 ARTI HBoV1: 52 
(3·08) 
NA ND 12 8·8 *,‡ 16 (30·8) 41·6 
Proenca-
Modena21 
Brazil 2010 – 
2012 
172 1 – 13 Chronic 
adeno-
tonsillar 
disease 
53 (31·1)  NA ND 9 62·2 NA 87 
Karadag-
Oncel22 
Turkey 2011 – 
2012 
200 <18 ILI 3 (1·5) * NA ND NA 0·9 1 (33·3) 51 
Ju23 
 
China 2011 – 
2013 
461 ≤ 4 ILI 13 (2·8) * NA ND 14 11·2 * 11 (84·6) * 57·92 
135 5 – 14 ILI 1 (0·7) * NA ND 14 7·6 * 1 (100) 48·96 
Kenmoe24 
 
Cameroon 2011 - 2013 347 ≤ 15 SARI 37 (10·6) NA ND 17 29·5 24 (64·9) * 65·4 
Rhedin25 
 
Sweden 2011 – 
2014  
121 ≤ 5 CAP 14 (12) NA ND 15 38·8 * NA 81 
240 ≤ 5 Control 50 (21) NA ND 15 37·3 * NA 56 
  
 
Zar26 
 
South-
Africa 
2012 – 
2014 
284 3 – 9 
months 
Pneumonia 37 (13) NA ND 33 † NA NA 97 † 
418 2 – 8 
months 
Control 32 (7·8) * NA ND 33 † NA NA 97 † 
Obuchi27 
 
Japan 2013 – 
2014 
104 ** < 12 ARTI HBoV1: 21 
(20·2) * 
1x10^3 – 
4·3x10^8 
copies/swab 
ND 21 9·1 * 7 (33) 85 
Jiang28 
 
China 2013 – 
2014 
7393 6 – 24 
months 
LRTI 654 (8·85) < 10^3 – 3·97 
× 10^9 
ND 9 NA 321 (49) NA 
Aktürk29 
 
Turkey 2013 – 
2014  
178 2 – 16  URTI / LRTI 8 (4·5) * NA ND 21 2·9 * 3 (37·5) * 78·6 
Finianos30 
 
Lebanon 2013 – 
2014  
236 ≤ 16 ARTI 36 (15) NA ND 17 37 28 (78) 70 
Goktas31 
 
Turkey 2014 – 
2015 
309 0 – 15  ARTI 35 (11) NA ND 22 † 27·2 † (64·8) †, ‡ 75·1 † 
* Percentage re-calculated, † including bacteria, ‡ including all subgroups, § from 760 children, ¶ of all subjects (not virus positive), || number of specimens, ** number of 
specimens negative for influenza by a rapid test kit, †† different number of serum samples than reported in n number, ‡‡ serodiagnosis done but data not shown in the 
publication, ALRI = acute lower respiratory infection, AOM = acute otitis media, ARTI = acute respiratory tract infection, ILI = influenza like illness, LOD = limit of 
detection, LRTI = lower respiratory tract infection, NA = not available, ND = not done, RTI = respiratory tract infection, SRTI = severe respiratory tract infection, URTI = 
upper respiratory tract infection, SARI = severe acute respiratory infection 
  
  
Major studies on human bocavirus detections in gastrointestinal illness, published May 23. 2011 to April 30. 2018 (see Jartti et al 2011 for an overview of earlier 
publications). References are listed below in supplementary. 
1st author Study site Study 
year 
n Age 
(years) 
Symptoms HBoV  Total HBoV 
DNA + n 
(%) and n 
(%) of 
HBoV1-4/ 
HBoV 
HBoV 
qPCR 
reported 
Copy 
number 
(copies/ml) 
HBoV 
Serodiagnosis 
n (%) 
Viruses 
tested 
Total 
viral co-
detections 
% 
HBoV co-
detections 
with other 
viruses, n 
(%) 
Total 
viral 
detections 
% 
Levican48 
 
Chile 1985 
– 
1986, 
1997 
– 
2004, 
2009 
– 
2010  
462 ≤ 5 AGE HBoV 89 (19·3) No NA ND 1 NA NA NA 
HBoV1 65 (73·0) *        
HBoV2 18 (20·2) *        
HBoV3 6 (6·7) *        
Teixeira de 
Sousa49 
 
Brazil 1994 
– 
1996, 
1998 
– 
2004 
762 < 5 AGE HBoV 44 (5·8) No NA ND 6 § NA 14 (31·8) NA 
HBoV1 11 (91·7) *,||        
HBoV3 1 (8·3) *,||        
Proenca-
Modena50 
 
Paraguay 2004 349 < 5 AGE (non-
bacterial) 
HBoV1 37 (10·6) Yes 1·88×10^4 
(median) 
ND 3 ‡ NA 15 (40·5) NA 
Mitui51 
 
Turkey 2004 
– 
2005 
150 < 5 Acute 
diarrhea 
HBoV 13 (8·7) No NA ND 5 20·7 10 (76·9) * 58 
HBoV1 1 (7·7)        
HBoV2A 7 (53·8)        
HBoV3 4 (30·8)        
  
HBoV4 1 (7·7)        
Bangladesh 2005 
– 
2006  
138 < 5 Acute 
diarrhea 
HBoV 87 (63·0) No NA ND 5 76·4 81 (91·0) * 89·1 
HBoV1 29 (38·7) ||        
HBoV2A 36 (48·0) ||        
HBoV3 8 (10·7) ||        
HBoV4 2 (2·7) ||        
Wang52 
 
China 2006 
– 
2007  
366 ≤ 13 AGE HBoV 44 (12·0) No NA ND 6 § NA 35 (79·5) * NA 
HBoV1 9 (20·5) *      9 (100) *  
HBoV2 33 (75) *      24 (72·7) *  
HBoV3 2 (4·5) *      2 (100) *  
Cashman53 Ireland 2006 
– 
2008 
155 All ages Non-bacterial 
GE 
HBoV 12 (7·7) No NA ND 4 NA 12 (100) 100 
HBoV1 2 (16·7)*, ||     100   
HBoV2 4 (33·3)*, ||     100   
HBoV3 2 (16·7)*, ||     100   
      Recombinations 4 (33·3) *, ||     100   
Jin54 
 
 
China 2006 
– 
2008  
632 < 5 AGE HBoV 162 (25·6) * Yes NA ND 5 NA NA 58·2 
HBoV1 27 (16·7) *  NA    20 (74·1) *  
HBoV2 129 (79·6) *  42·3 
(mean) 
   94 (72·9)  
HBoV3 6 (3·7) *  NA    6 (100)  
162 < 5 Control HBoV 24 (14·8) * Yes NA ND 5 NA NA 19·1 * 
  
HBoV1 4 (16·7) *  NA      
HBoV2 20 (83·3) *  54·3 
(mean) 
     
Risku55 
 
Finland 2006 
– 
2008 
878 < 15 AGE HBoV 85 (9·7) No NA ND 7 § NA 69 (81·2) * NA 
HBoV1 49 (57·0) *      42 (85·7)  
HBoV2 29 (33·7) *      21 (72·4)  
HBoV3 8 (9·3) *      7 (87·5)  
112 < 15 Control HBoV 6 (5·4) No NA ND 7 § NA 0 (0) NA 
HBoV1 2 (33·3) *        
HBoV2 2 (33·3) *        
HBoV3 2 (33·3) *        
Chhabra56 
 
USA 2008 
– 
2009  
782 < 5 AGE HBoV 11 (1·4) Yes NA ND 8 13·1 7 (21·2) *, 
† 
40·8 † 
499 < 5 Control HBoV 12 (2·4) Yes NA ND 8 1·3   
Medici57 
 
Italy 2008 
– 
2009  
712 < 154 
months 
AGE HBoV 23 (3·2) No NA ND 3 ‡ 1·8 * 1 (4·3) * 7·7 * 
HBoV1 5 (21·7)        
HBoV2 10 (43·5)        
HBoV3 8 (34·8)        
Rimoldi58 
 
Italy 2008 
– 
2009  
154 ≤ 252 
months 
AGE HBoV 21 (13·6) Yes NA ND 12 ‡‡ 13·1 *, ‡‡ 7 (33·3) * 64·3 
Romani59 
 
Iran 2008 
– 
227 < 18 AGE HBoV 24 (10·57) No NA ND 1 NA NA NA 
67 > 18 AGE HBoV 3 (4·48) No NA ND 1 NA NA NA 
  
2010     HBoV1 3 (17·6) *, ||        
HBoV2 13 (76·5) *, 
|| 
       
HBoV3 1 (5·9) *, ||        
Alam60 
 
Pakistan 2009 365 < 5 AGE HBoV 47 (13) Yes NA ND 2 12·9 * 46 (98) 97·8 * 
HBoV1  26 (94) ||        
HBoV2 1 (3) ||        
HBoV3 1 (3) ||        
Khamrin61 
 
Japan 2009 
– 
2010  
177 < 5 AGE HBoV 11 (6·2) No NA ND 12 NA 9 (81·8) NA 
HBoV1 7 (63·6) *        
HBoV2A 4 (36·4) *        
Lasure62 
 
India 2009 
– 
2011  
418 ≤ 5 AGE HBoV 24 (5·7) No NA ND 6 NA 5 (21) NA 
HBoV1 15 (62)        
HBoV2 4 (17)        
HBoV3 2 (8)        
HBoV4 3 (12)        
Paloniemi63 
 
Finland 2009 
– 
2011  
172 Children AGE HboV 14 (8·1) * Yes NA 10 (33·3) *, †, 
**  
1 NA 12 (85·7) * NA 
HBoV1 3 (21·4) *      2 (66·7) *  
HBoV2 10 (71·4) *      9 (90·0) *  
HBoV3 1 (7·1) *      1 (100) *  
  
238 Children AGE+ARTI HBoV 37 (15·5) * Yes NA 10 (33·3) *, †, 
** 
1 NA 7 (18·9) * NA 
HBoV1 22 (59·5) *      NA  
HBoV2 13 (35·1) *      5 (38·5) *  
HBoV3 2 (5·4) *      2 (100) *  
Babkin64 
 
Russia 2010 
– 
2011  
1781 ≤ 3 AGE HBoV 34 (1·9) No NA ND 4 11·5 * 15 (44·1) *  39·7 
HBoV1 11 (32·4) *      5 (45·5) *  
HBoV2 23 (67·6) *      10 (43·5) *  
Monavari65 
 
Iran 2010 
– 
2011 
200 1-5  AGE HBoV 16 (8) Yes NA ND 6 †† NA 0 (0) NA 
Thongprachum66 
 
Japan 2010 
– 
2012  
751 ≤ 15 AGE HBoV 48 (6·4) No NA ND 14 26·7 * 38 (79·2) * 70·3 
Tymentsev67 
 
Russia 2010 
– 
2012  
5250 ≤ 5 AGE 
(hospitalized) 
HBoV 62 (1·2) No NA ND 11 †† NA 28 (45·2) * NA 
HBoV1 24 (38·7)      13 (54·2) *  
HBoV2 35 (56·5)      14 (40) *  
HBoV3 1 (1·6)      0 (0)  
HBoV4 2 (3·2)      1 (50) *  
252 ≤ 5 Control HBoV 1 (0·3) No NA ND 11 †† NA NA NA 
Zhang68 
 
China 2010 
– 
2012  
1128 < 14 Diarrhea HBoV1 17 (1·5) Yes NA ND 6 11·1 * 4 (23·5) 32·8 
Khamrin69 Thailand 2011 222 < 5 Diarrhoea HBoV 17 (7·7) No NA ND 12 § NA 10 (58·8) NA 
  
 HBoV1 11 (64·7)        
HBoV2A 3 (17·6) *        
HBoV3 2 (11·8) *        
HBoV4 1 (5·9) *        
Rovida70 
 
Italy 2011 
– 
2012  
689 ≤ 96 GI symptoms HBoV 17 (2·5) * No NA ND 12 22·3 * 12 (70·6) * 35·7 
Soares Campos71 
 
Brazil 2012 105 ≤ 5 AGE HBoV 44 (42) No NA ND 4 18·1 12 (27) 68·6 * 
HBoV1 3 (30) ||        
HBoV2A 7 (70) ||        
Tang72 
 
Taiwan 2012 
– 
2013  
110 ≤ 18 AGE HBoV  4 (3·5) No NA ND 1 NA NA NA 
Zhou73 
 
China 2012 
– 
2013  
346 < 6 AGE HBoV 60 (17·34) No NA ND 6 NA 26 (43·33) 35·3 
HBoV1 9 (56·3)*, ||        
HBoV2 7 (43·8)*, ||        
La Rosa74 
 
Albania 2013 
– 
2015 
142 Children AGE HBoV 13 (9·2) * No NA ND 3 § NA 13 (100) NA 
HBoV1 12 (92·3) *        
HBoV2 1 (7·7)*        
Lee75 
 
South 
Korea 
2015 155 < 6 GE 
symptoms 
HBoV1 10 (6·5) No NA ND 4 § NA 3 (30) * NA 
Nawaz76 U.K NA 2256 all ages GE HBoV 149 (6·6) Yes 4·56x10^3 
– 
ND 1 NA 88 (59·1) NA 
  
 4·56x10^4  
HBoV1 6 (12·0) *        
HBoV2 34 (68·0) *        
HBoV3 10 (20·0) *        
2124 all ages Control HBoV 175 (8·2) Yes 4·56x10^3 
– 
4·56x10^4 
ND 1 NA 87 (49·7) NA 
HBoV1 25 (42·4) *        
HBoV2 20 (33·9) *        
HBoV3 14 (23·7) *        
* Percentages re-calculated, † in the whole study population, ‡ previously tested negative for certain pathogens, § Samples previously tested for certain pathogens, ¶, AGE = 
acute gastroenteritis, || percentages calculated out of total typed HBoV (not all HBoVs typed), ** different number of serum samples than reported in n number, †† only co-
infections with other viruses tested, ‡‡ including bacteria, ARTI = acute respiratory tract infection, GE = gastroenteritis, GI = gastrointestinal, NA = not available, ND = not 
done 
  
  
Major studies on human bocavirus respiratory tract infections in adults, published May 23. 2011 to April 30. 2018 (see Jartti et al 2011 for an overview of earlier 
publications). References are listed below in supplementary. 
1st author 
 
Study site Study 
year 
n Age (years) Diagnosis HBoV 
DNA, n (%) 
Viruses 
tested 
Copy 
number 
qPCR 
reported 
HBoV-1 
Serodiagnosis 
n (%) 
Total viral 
co-
detections 
% 
HBoV co-
detections 
with other 
viruses, n 
(%) 
Total viral 
detections 
(%) 
Aronen32 Finland 2007 – 
2009 
438 65 – 100 Respiratory 
symptoms 
HBoV1: 2 
(0·5) *, § 
16 NA No No acute 
HBoV1 - 4 
infection in 
396 episodes 
13·8 * NA 37 
   200 65 – 100 Respiratory 
symptoms 
with dyspnea 
HBoV1: 1 
(0·6) *, § 
16 NA No  15·8 * NA 38 
   238 65 – 100 Respiratory 
symptoms 
without 
dyspnea 
HBoV1: 1 
(0·5) *, § 
16 NA No  11·4 * NA 37 
   291 65 – 100 No respiratory 
symptoms 
HBoV1: 0 
(0) *, § 
16 NA No  20·9 * NA 23 
Guido33 
 
Italy 2008 – 
2009  
22 15 – 64  ILI HBoV1: 10 
(45·5) * 
4 NA No ND 26·7 *, ‡ (49·1) ‡ 67·2 ‡ 
42 >64 ILI HBoV1: 14 
(33·3) * 
4 NA No ND    
Memish34 
 
Saudi 
Arabia 
2009 172 41 (mean) Healthcare 
workers 
0 (0) 18 NA No ND NA 0 (0) 12·8 
Paño-
Pardo35 
 
Spain 2009 45 Pregnant ILI 1 (2·2) * 12 NA No ND 2·2 * 0 (0) 66·58 
  
Liu36 
 
China 2009 - 
2010 
1014 ≥ 18 ARTI 4 (0·4) 16 †, ¶ NA Yes ND NA 1 (25) NA 
Lu37 
 
China 2009 – 
2010 
266 14 – 25  URTI 27 (10·15) 11 NA No ND 17·5 * 12 (44·4) * 42·86 
303 26 – 65 URTI 21 (6·93) 11 NA No ND 7·2 * 6 (28·6) * 36·63 
27 ≥ 66 URTI 1 (3·70) 11 NA No ND 0 0 (0) 22·22 
Pilorge38 
 
France 2009 – 
2010  
78 Pregnant ILI 1 (1·3) * 16 NA Yes ND 0 0 (0) 65 
Dia39 
 
Senegal 2009 - 
2011 
232 ≥50 ILI 1 (0·4) * 16 NA Yes ND 11·4 * NA 56·9 
Lu40 
 
China 2009 - 
2011 
981 || 14 – 91 URTI 2 (0·2) 15 NA No ND NA NA 41·1 * 
Feng16 
 
China 2009 – 
2013 
2629 15 – 49  ALRI 9 (0·3) * 7 NA Yes ND 7·1 * (75) ‡ 19·8 * 
1790 50 – 64  ALRI 6 (0·3) * 7 NA Yes ND 7·8 *  16·4 * 
3313 ≥ 65 ALRI 11 (0·3) * 7 NA Yes ND 5·8 *  14·7 * 
Serin41 
 
Turkey 2010 50 ≥ 18 CAP 0 (0) 26 NA No ND 10 * 0 (0) 36 
Ghietto42 
 
Argentina 2010 19 ≥ 16 LRTI HBoV1: 5 
(26·3) * 
8 ¶ NA No ND NA 0 (0) NA 
Xu20 
 
China 2010 – 
2011 
1774 >15 ARTI HBoV1: 6 
(0·37) 
12 NA Yes ND 8·8 *, ‡ 4 (60) 38·7 
Koul43 India 2011 – 
2012 
233 40 – 100 AECOPD 1 (0·4) 18 NA Yes ND 8·7 * 0 (0) 19·7 
  
 
Noh44 
 
South-
Korea 
2011 – 
2012  
1983 ≥18 ILI 0 (0) 17 NA No ND 5·6 0 (0) 52·1 
Ju23 
 
China 2011 – 
2013 
135 15 – 24 ILI 1 (0·7)* 14 NA Yes ND 12·2 * 1 (100) 36·30 
167 25 – 59 ILI 1 (0·60) 14 NA Yes ND 13·1 * 0 (0) 36·53 
42 ≥ 60 ILI 1 (2·4)* 14 NA Yes ND 21·4 * 1 (100) 33·33 
Remolina45 
 
Colombia 2012 91 ≥ 18 SRTI 26 (28·6) 19 NA No ND 41·3 15 (57·7 ) * 69·2 
Ye46 
 
China 2012 – 
2015 
967 > 60 ARTI 0 (0) 17 NA No ND 9·8 * 0 (0) 31·64 
Dai47 
 
China 2014 81 71±10 AECOPD 6 (7·4) 18 NA No ND 31·6 * NA 38·3 * 
Goktas31 
 
Turkey 2014 – 
2015  
536 > 15  ARTI 56 (10·4) * 22 † NA Yes ND 34·5 † (64·8) †, ‡ 70·9 † 
* Percentages re-calculated, † Including bacteria, ‡ in all subgroups, § not all samples tested for HBoV, ¶ Only bocavirus positive specimens tested, || number of specimens, 
AECOPD = acute exacerbtions of chronic obstructive pulmonary disease, ALRI = acute lower respiratory infection, ARTI = acute respiratory tract infection, CAP = 
community acquired pneumonia, COPD = chronic obstructive pulmonary disease, ILI = influenza like illness, LRTI = lower respiratory tract infection, NA = not available, 
ND = not done, SRTI = severe respiratory tract infection, URTI = upper respiratory tract infection 
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